Diabetic patients prescribed with Byetta prior to 2007 and had since developed acute pancreatitis may be able to receive personal injury compensation from Amylin.
Byetta is a synthetic prescriptive drug used to control blood sugar levels of people suffering from type 2 diabetes or diabetes mellitus type 2. It is manufactured by Amylin Pharmaceuticals and distributed in the US by Eli Lilly & Co. The twice-daily injectable Byetta and its once-weekly counterpart Bydureon, generic name exenatide, have been found to be efficacious in reducing the glucose levels in blood by mimicking the effects of incretins (incretin mimetic), a hormone released by the intestine in the blood when food is introduced, which in turn increases insulin production of the pancreas. Exenatide also reduces the appetite, which helps in weight loss. Exenatide has been approved by the Food and Drug Administration since 2005.
There are side effects associated with Exenatide, including nausea, hypoglycemia, excess sweating, headache and gastrointestinal distress. However, it is the unfortunate effect on the pancreas that has brought attention to Exenatide. The direct action of Exenatide is on the pancreas, which dictates the release of glucose-processing insulin in the blood. In some cases, patients who have been prescribed with Byetta developed acute pancreatitis, the sudden inflammation of the pancreas that can lead to serious health complications and death.
Because of this side effect, the FDA decreed in 2007 that Byetta labels should include a warning about the risk of developing pancreatitis even though the association has yet to be definitively established. Nevertheless, if you or someone you know is a Byetta user prior to 2007 and developed (or died from) acute pancreatitis, it is possible that a claim for personal injury may be successful. A lawyer conversant with the laws applicable to a Byetta lawsuit should be consulted to assess the situation. It is noteworthy that in some studies, exenatide use increases the risk of developing problems with the thyroid in rats, including cancer.